Ten steps to developing a national agenda to address financial conflicts of interest in industry sponsored clinical research

Accountability in Research

Volumn 12, Issue 2, 2005, Pages 139-155

  Tereskerz, Patricia M ^a   Moreno, Jonathan ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; CONFLICT OF INTEREST; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; HUMAN; INDUSTRY; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; MEDICAL RESEARCH; PERSONNEL; PRACTICE GUIDELINE; PUBLIC RELATIONS; STANDARD; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

BIOMEDICAL RESEARCH; CLINICAL TRIALS; CONFLICT OF INTEREST; DISCLOSURE; GUIDELINES; HUMANS; INDUSTRY; INTERINSTITUTIONAL RELATIONS; RESEARCH PERSONNEL; RESEARCH SUPPORT; UNITED STATES;

EID: 32944480779     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989620590957229     Document Type: Article

References (53)

1. 21 CFR 54 et seq.
2. 21 CFR pt. 54, and applicable portions of parts 312, 314, 320, 330, 601, 807, 812, 814, and 860.
3. 42 CFR Section 50.603.
4. American Association of Medical Colleges. (1990). Guidelines for Dealing with Faculty Conflicts of Commitment and Conflicts of Interest in Research. Washington DC.: AAMC.
5. American Association of Medical Colleges. (2001). Protecting Subjects, Preserving Trust, Promoting Progress-Policy and Guidance for the Oversight of Individual Financial Conflicts of Interest in Human Subjects Research. Available at http://www.aamc.org.
6. Andrews, L.B. (2000). Money Is Putting People at Risk in Biomedical Research, Chronicle of Higher Education (March 10) at B4, B5.
7. Angell, M. (2000). Is Academic Medicine for Sale? New England Journal of Medicine, 342: 1516-1518.
8. Angell, M. (2004). The Truth About the Drug Companies. New York: Random House.
9. Association of American Universities. (2001). Framework Document on Managing Financial Conflicts of Interest Report on Individual and Institutional Financial Conflicts of Interest. Available at http:www.aau.edu/reports/frwkCOI.html.
10. Bayh-Dole Act. (1980). Pub L No. 96-517.
11. Bekelman, J.E., Li, Y., and Gross, C.P. (2003). Scope and Impact of Financial Conflicts of Interest in Biomedical Research, Journal of the American Medical Association, 289: 454-465.
12. Bero, L.A., and Rennie, D. (1996). Influences on the Quality of Published Drug Studies, International Journal of Technological Assessment in Health Care, 12: 2009-2013.
13. Birch, D.M., and Cohn, G. (2001). Standing Up to Industry: As Corporations Increasingly Hold Their Purse Strings, Many Researchers Feel Pressed to Deliver Favorable Results, Baltimore Sun (June 26) at 1A.
14. Bodenheimer, T. (2000). Uneasy Alliance-Clinical Investigators and the Pharmaceutical Industry, New England Journal of Medicine, 342: 1539-1544.
15. Boyd, E., and Bero, L. (2000). Assessing Faculty Financial Relationships With Industry: A Case Study, Journal of the American Medical Association, 184: 2209-2214.
16. Chaudhry, S., Schroter, S., Smith, R., and Morris, J. (2002). Does Declaration of Competing Interests Affect Readers' Perceptions? A Randomized Trial, British Medical Journal, 325: 1391-1392.
17. Cho, M.K., Shohar, R., Schissel, A., and Rennie, D. (2000). Policies on Faculty Conflicts of Interest at U.S. Universities, Journal of the American Medical Association, 284: 2203-2208.
18. Correspondence to Arthur J. Lawrence, Assistant Surgeon General, from Mary Faith Marshall, Chairperson for NHRRPAC, dated August 23, 2001.
19. Davidoff, F., DeAngellis, C.D., Drazen, J.M., Hoey, J., Horton, R., Kotzin, S., Nicholls, M.G., Nylenna, M., Overbeke, A.J.P.M., Sox, H.C., Van Der Weyden, M.B., and Wilkes, M.S. (2001). Sponsorship, Authorship, and Accountability, New England Journal of Medicine, 345: 825-826.
20. Davidson, A. (1986). Source of Funding and Outcome of Clinical Trials, Journal of General Internal Medicine, 1: 155-158.
21. Department of Health and Human Services (2004). Final Guidance: Financial Relationships and Interest in Research Involving Human Subjects: Guidance for Human Subject Protection. Replacing Department of Health and Human Services (3/31/2003). Draft: Financial Relationships and Interest in Research Involving Human Subjects: Guidance for Human Subject Protection. May 3, 2004.
22. Department of Health and Human Services. (2005). Supplemental Standards of Ethical Conduct and Financial Disclosure Requirements for Employees of the Department of Health and Human Services, Federal Register (February 3): 5543-5565.
23. Emanuel, E., and Steiner, D. (1995). Institutional Conflicts of Interest, New England Journal of Medicine, 332: 262-267.
24. Friedberg, F., Saffran, B., Stinson, T.J., Nelson, W., and Bennett, C.L. (1999). Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology, Journal of the American Medical Association, 282: 1453-1457.
25. General Accounting Office (GAO). (2001). Report to the Ranking Minority Member, Subcommittee on Public Health, Committee on Health, Education, Labor, and Pensions, U.S. Senate. GAO-02-89 (November).
26. Guterman, L. (2001). Medical Journals Issue Joint Policy on Research Supported by Business, Chronicle of Higher Education (October 5) at A28.
27. Hensley, S., and Abboud, L. (2004). Negative Results Often Fail to Get Published in Journals; Some Blame Drug Industry, Wall Street Journal (June 4): B3.
28. Hippocrates Meets Mammon. (1990). The Economist (September 22, 1999): 195.
29. International Committee of Medical Journal Editors. (2004). Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Updated 2004. Available at http://www.icmje.org.
30. Kaplan, S., and Brownlee, S. (1999). Dying for a Cure: Why Cancer Patients Often Turn to Risky Experimental Treatments-and Wind Up Paying With Their Lives, U.S. News & World Report, (October 11): 34.
31. Kassirer, J.P. (2002). Financial Conflict of Interest: An Unresolved Ethical Frontier, American Journal of Law and Medicine, 27: 149-162.
32. Kim, S.Y.H, Millard, R.W., Nisbet, P., Cox, C., and Caine, E.D. (2004). Potential Research Participants' Views Regarding Researcher and Institutional Financial Conflicts of Interest, Journal of Medical Ethics, 30: 73-79.
33. Kuszler, P.C. (2001). Curing Conflicts of Interest in Clinical Research: Impossible Dreams and Harsh Realities, Widener Law Symposium Journal, 8: 115-151.
34. Lexchin, J., Bero, L.A., Djulbegovic, B., and Clark, O. (2003). Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review, British Medical Journal, 326: 1167-1170.
35. Lo, B., Wolf, L.E., and Berkeley, A. (2000). Conflict-of-Interest Policies for Investigators in Clinical Trials, New England Journal of Medicine, 343: 1616-1620.
36. Martin, J.B., and Kasper, D.L. (2000). In Whose Best Interest? Breaching the Academic-Industrial Wall, New England Journal of Medicine, 343(22): 1646-1649.
37. McCrary, S.V., Anderson, C.B., Jakovljevic, J., Khan, T., McCullough, L.B., Wray, N.P., and Brody, B.A. (2000). A National Survey of Policies on Disclosure of Conflicts of Interest in Biomedical Research, New England Journal of Medicine, 343: 1621-1626.
38. Moses, H., Braunwald, E., Martin, J.B., and Their, S.O. (2002). Collaborating With Industry-Choices for the Academic Medical Center, New England Journal of Medicine, 347: 1371-1375.
39. Moses, H., and Martin, J.B. (2001). Academic Relationships With Industry: A New Model for Biomedical Research, Journal of the American Medical Association, 285: 933-935.
40. National Institutes of Health. (August 15, 2000). Transcript: Conference on Human Subject Protection and Financial Conflicts of Interest. A Non-Federal Perspective: Thomas S. Bodenheimer. Available at http://www.ohrp.osophs.dhhs.gov/coiconflictofinterest/8-15.htm.
41. Office of Inspector General. (2000). Recruiting Human Subjects: Sample Guidelines for Practice. Washington, DC: Office of Inspector General, pp. 1-23.
42. Office of Management and Budget. (2001). No. 0910-0396/Forms FDA 3454 (6/02) and 3455 (7/01).
43. PhRMA Adopts Principles for Conduct of Clinical Trials and Communication of Clinical Trial Results. (2002). Available at http://www.phrma.org.
44. Public Health Service. (1995). Responsibility of Applicants for Promoting Objectivity in Research. Available at http://grants.nih.gov/grants/guide/notice-files/not95-179.html.
45. Rochon, P.A., Berger, P.B., and Gordon, M. (1998). The Evolution of Clinical Trials: Inclusion and Representation, Canadian Medical Association Journal, 159: 1373-1374.
46. Rodwin, M.A. (1995). Strains in the Fiduciary Metaphor: Divided Physician Loyalties and Obligations in a Changing Health Care System, American Journal of Law & Medicine, 21: 241. Quoting Luke 16.13 (King James).
47. Schroter, S., Morris, J., Chaudhry, S., Smith, R., and Barrah, H. (2004). Does the Type of Competing Interest Statement Affect Readers' Perceptions of the Credibility of Research? Randomised Trial, British Medical Journal, 328: 742-743.
48. Shamoo, A.E. (2001). Adverse Events Reporting-The Tip of an Iceberg, Accountability in Research, 8: 197-218.
49. Spece, R.G., Shim, D.S., and Buchanan, A.E. (1996). Conflicts of Interest in Clinical Practice and Research. New York: Oxford University Press.
50. Stelfox, H.T., Chua, G., O'Rourke, K., and Detsky, A.S. (1998). Conflict of Interest in the Debate Over Calcium-Channel Antagonists, New England Journal of Medicine, 101: 106-108.
51. Stolberg, S.G. (2000). Teenager's Death Is Shaking Up Field of Human Gene-Therapy Experiments, New York Times (January 27).
52. Turkington, R.C. (1990). Legacy of the Warren and Brandeis Article: The Emerging Unencumbered Constitutional Right to Informational Privacy, Northern Illinois University Law Review, 10: 479.
53. Tereskerz, P. (2003). Research Accountability and Financial Conflicts of Interest in Industry-Sponsored Clinical Research: A Review, Accountability in Research, 10: 137-158.